Brian Pepin is the CEO and founder of Rune Labs. Brian holds an MSEE in electrical engineering from UC Berkeley and a BSEE from the University of Washington. Prior to starting Rune, Brian spent nearly five years at Verily Life Sciences. Top 3 Takeaways * It makes sense to use neuromodulation therapies for neurological and psychiatric disorders that inherently fluctuate over time. * Neuromodulation data is siloed and that slows down research and translation. * Closed-loop DBS can enable novel, more efficacious therapies. Show Notes * [0:47] Brian’s background. * [1:50] The Google phase. * [3:10] Brian’s transition into Rune Labs. * [3:30] Rune in a nutshell. * [4:32] Unmet needs for brain diseases. * [5:58] Why neuromodulation instead of drugs. * [7:30] Need for adaptive therapies. * [8:53] Impact of neuromodulation in Parkinson’s Disorder. * [10:54] Who fits the bill for DBS. * [13:30] Siloed data in neuromodulation. * [15:15] Competition in DBS. * [16:45] Initial application of closed-loop DBS is auto-tune. * [17:30] Closed-loop can enable therapies. * [19:03] Software development in DBS devices. * [20:10] Partnerships between medical device companies and AI companies. * [21:27] Long-term vision for Rune. Selected Links * Strive PD patient-facing application Related Podcasts * 021 – Cory Inman * 020 – Mary Beth Henderson * 016 – Jim Cavuoto Disclaimer